SpicyIP

MARCH 30, 2025

CRI Guidelines 2025 is out for Public Consultations! The Draft Guidelines for Examination of Computer-Related Inventions (CRI), 2025, has been published for public consultation. Interested stakeholders can provide their comments on the guidelines by April 15, 2025. Read the post for more details. Part I] Safe Harbor in Jeopardy?

Personality Rights 59

Personality Rights Trademark Intellectual Property Copyright 59

SpicyIP

FEBRUARY 23, 2025

on 14 February, 2025, (Delhi HC) Manash Lifestyle Pvt. on 14 February, 2025 (Delhi HC) TThe plaintiff, a manufacturer of Ayurvedic and Unani medicines, filed a suit seeking a permanent injunction against the defendants for trademark and copyright infringement of its well-known ‘KUKA’ brand. Read the post for more.

Confidentiality 59

Confidentiality Trademark Copyright Infringement Music 59

IP Law 360

OCTOBER 7, 2024

billion antitrust settlement with athletes suing over the organization's name, image and likeness compensation rules, and set a hearing for final approval on April 7, 2025, which coincidentally is also the date of the men's basketball national championship game in San Antonio.

Settlement 52

Settlement 52

SpicyIP

FEBRUARY 23, 2025

on 14 February, 2025, (Delhi HC) Manash Lifestyle Pvt. on 14 February, 2025 (Delhi HC) TThe plaintiff, a manufacturer of Ayurvedic and Unani medicines, filed a suit seeking a permanent injunction against the defendants for trademark and copyright infringement of its well-known ‘KUKA’ brand. Read the post for more.

Confidentiality 52

Confidentiality Trademark Copyright Infringement Music 52

LexBlog IP

JUNE 13, 2023

announced that they reached a settlement and license agreement with Johnson & Johnson regarding AVT04, Alvotech’s proposed biosimilar to STELARA (ustekinumab) in the United States. The post Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J appeared first on Big Molecule Watch.

Settlement 52

Settlement Marketing Marketing Licensing 52

Velocity of Content

FEBRUARY 11, 2025

The following is an excerpt from the ebook, 2025 Copyrighted Content Usage Trends, which draws on data from the 2025 Information Seeking and Usage Study to offer insights into how employees think about, use, and share copyrighted content today, including with AI tools. Since 2007, CCC has partnered with Outsell, Inc.

Copyright 52

Copyright Copyright Infringement Reporting Licensing 52

JD Supra Law

MARCH 18, 2025

On February 28, 2025, the FDA approved Celltrions Stoboclo / Osenvelt (denosumab-bmwo) as the third company to receive FDA approval of biosimilars of Amgens Prolia / Xgeva (denosumab).. By: Venable LLP

Settlement 69

Settlement Litigation 69

LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

JD Supra Law

FEBRUARY 4, 2025

TheNCAAand a coalition of states led by Tennessee reached a settlement in their lawsuit against the NCAA, Tennessee Attorney General Jonathan Skrmetti announced Jan. By: Kaufman & Canoles

Settlement 66

Settlement Law 66

LexBlog IP

AUGUST 30, 2023

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

Settlement 40

Settlement Confidentiality Marketing Marketing 40

JD Supra Law

JANUARY 29, 2025

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA litigation regarding Celltrions denosumab biosimilar, CT-P41.. By: Goodwin

Settlement 69

Settlement Litigation 69

JD Supra Law

MARCH 11, 2025

On March 7, 2025, the District Court for the District of New Jersey entered a Stipulation and Order of Dismissal Without Prejudice in view of a settlement agreement between Amgen and Fresenius Kabi resolving the BPCIA litigation regarding Freseniuss denosumab biosimilar, FKS518.. By: Goodwin

Settlement 60

Settlement Litigation 60

JD Supra Law

DECEMBER 13, 2023

Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA®. If SB17 is approved by the FDA, the license period in the United States will begin on February 22, 2025.

Litigation 69

Litigation Settlement Licensing Reporting 69

LexBlog IP

FEBRUARY 23, 2024

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Per the settlement agreement, AVT04 can be marketed in the U.S., subject to regulatory approval, no later than February 21, 2025.

Settlement 40

Settlement Marketing Marketing Licensing 40

LexBlog IP

DECEMBER 13, 2023

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.

Litigation 52

Litigation Settlement Licensing Marketing 52

The IPKat

JANUARY 12, 2025

The Enlarged Board has accepted the case as G 2/24 and invited stakeholders and the President of the EPO to provide comments by 17 April 2025. Settlement Dynamics: Patentees may need to negotiate with interveners as well as original appellants to terminate appeal proceedings.

Patent Infringement 64

Patent Infringement Government Settlement Patent 64

LexBlog IP

MARCH 6, 2024

announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Settlement Litigation 52

JD Supra Law

AUGUST 3, 2023

Notably, since our last update, Janssen and Amgen reached a settlement allowing for the launch of Amgen’s biosimilar to Stelara no later than January 1, 2025. Since the enactment of the Biologics Price Competition and Innovation Act (BPCIA), 41 biosimilars have been approved, 22 of which have launched. By: Morgan Lewis

Settlement 52

Settlement Litigation Patent 52

LexBlog IP

MARCH 6, 2024

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. The agreement allows Biocon to launch in the United States in February 2025, pending FDA approval. 10,961,307, which claims methods of treating ulcerative colitis with ustekinumab. Amgen secured a U.S.

Marketing 40

Marketing Marketing Settlement Licensing 40

The IPKat

MARCH 13, 2025

The judgment carefully considers some of the issues around how trade marks are described and presented on the register, with the court finding that the mark was validly registered: Babek International Ltd v Iceland Foods Ltd [2025] EWHC 547 (IPEC) What is the case about?

Registration 45

Registration Intellectual Property Litigation Settlement 45

SpicyIP

MARCH 1, 2025

1925 As of 26th February, 2025 , Kindle users will no longer be able to use the feature Download or Transfer via USB, for Kindle Purchased books, as Amazon is discontinuing the feature. After a fairly large settlement in the US, restrictions were put on Kindle to never remove or modify books purchased in the US without the users consent.

Copying 59

Copying Editing Licensing Copyright 59

Bio Law Blog

JUNE 21, 2020

On May 28, Alexion and Amgen entered into a confidential settlement agreement to terminate the IPRs. Pursuant to the terms of the settlement agreement, effective March 1, 2025 (or earlier in certain circumstances), Alexion grants to Amgen a nonexclusive, royalty-free license under U.S. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

SpicyIP

JULY 8, 2024

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Anything we are missing out on?

Invention 59

Invention Art Trademark Patent Application 59

The IPKat

FEBRUARY 29, 2024

It is likely therefore that it will stand to be determined by a High Court judge some time in 2025. It is unlikely that the Mitchell and Redding estates will be prepared to settle for anything less than a very substantial payout – something that Sony does not, at this stage – appear to be minded to agree.

Reporting 111

Reporting Copyright Contracts Settlement 111

SpicyIP

MARCH 15, 2024

Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. If the trial spills over to 2025, the defendants will have to bear the cost for that as well. The parties commenced joint negotiations in 2021.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. With the enactment of the MSME Act,2006; an effective mechanism has emerged, enhancing the MSME claim settlement procedure and striving to make it more accessible.

Settlement 52

Settlement Intellectual Property Registration Designs 52

LexBlog IP

NOVEMBER 5, 2023

According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.” .” (CMS’s position on this has been challenged in pending litigation.)

Marketing 40

Marketing Marketing Government Litigation 40

Patently-O

JULY 31, 2024

In that case, the NPE patentee was able to reach a $600+ million settlement agreement with RIMM that many saw as a holdup cost to prevent a shutdown of the then-leading device provider. MercExchange decision. Adam Mossoff, Injunctions for Patent Infringement: Historical Equity Practice Between 1790 – 1882 , Harvard J.

Patent 53

Patent Patent Infringement Law Settlement 53

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . No earlier than June 30, 2023 per settlement. No earlier than September 30, 2023 per settlement. No earlier than July 1, 2023 per settlement. No earlier than January 31, 2023 per settlement. January 2021.

Litigation 52

Litigation Settlement Marketing Marketing 52

LexBlog IP

JANUARY 25, 2024

According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.” .” (CMS’s position on this has been challenged in pending litigation.)

Marketing 40

Marketing Marketing Licensing Litigation 40

Patently-O

MAY 15, 2024

This wave of RFCs includes significant proposals aimed at adjusting patent fees for fiscal year 2025, refining terminal disclaimer practices, and addressing the impact of artificial intelligence on prior art and patentability. 325(d) considerations, parallel and serial petitions, and settlement-related terminations.

Art 45

Art Intellectual Property Designs Design 45

LexBlog IP

FEBRUARY 18, 2024

The remaining proposals are entitled: “ PTAB Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement.” In 2025 we will likely have a new Director, and perhaps a new Fintiv memo.

Settlement 52

Settlement Publishing Patent Intellectual Property 52

Herbert Smith Freehills

SEPTEMBER 10, 2021

Under this model , SA’s emissions would peak between 2020 and 2025 as reflected in South Africa's National Climate Change Response Policy and then plateau for approximately a decade before declining in absolute terms. Through the strategy Angola intends to reach a seventy per cent renewable capacity by 2025.

Government 64

Government Reporting Publishing Settlement 64

The IPKat

MARCH 17, 2025

The case is Morley's (Fast Foods) Ltd v Nanthakumar & Ors [2025] EWCA Civ 186. The signs in question were: There was an earlier dispute between the parties, leading to a settlement agreement requiring the defendants to stop using their then brand Mowleys and approving the use by Metros of the following sign.

Settlement 64

Settlement Branding Brands Branding 64

43(B)log

FEBRUARY 27, 2025

Casden, 2025 WL 579641, 2:21-cv-01149-ODW (RAOx) (C.D. 21, 2025) I just posted about courts increasing openness to disgorgement. Casden negotiated and signed the Settlement Agreement on behalf of Hologenix. Multiple Energy Technologies, LLC v. MET sued Hologenix for false advertising, and they settled in 2020.

False Advertising 52

False Advertising Settlement Advertising Advertising 52

TorrentFreak

DECEMBER 3, 2024

This final judgment and settlement marks the culmination of a six-year legal battle against one of the most popular South Asian services offering pirated content, Jadoo TV, and its CEO, who was found personally liable for the damages caused by his and his company’s copyright infringement,” says Chris Kuelling, executive director of IBCAP.

Copyright Infringement 56

Copyright Infringement Settlement Copyright Litigation 56

Technology & Marketing Law Blog

MARCH 19, 2025

The settlement says: subdivisions (a)(3), (a)(4)(A), and (a)(5) of California Business and Professions Code section 22677 violate the First Amendment of the United States Constitution facially and as applied to Plaintiff The state also must pay X $345,576 to cover its challenge costs. settlement filed Feb. Great job, California.

Social Media 59

Social Media Law Settlement Reporting 59